source
- GSK prepares for patent cliff with $2.5B cost-cutting planThe pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss of patents important to its HIV drug franchise.
- STAT+: Bracing for another Fauci hearingPlus: Democrats take on Trump over IVF, and Trump's White House releases a new science funding blueprint.